Abstract
We sought to determine whether oral fluid can be used to assess serum human papillomavirus (HPV) antibody status by enrolling women who had received a prophylactic HPV-16 vaccine in a new follow-up study. After the prophylactic HPV-6/11/16/18 vaccine was licensed in the United States, we administered it to consenting participants. With serologic findings used as the reference standard, The sensitivity of oral fluid was 49.6% (95% confidence interval [CI], 42.0%-57.3%) before and 100% (95% CI, 92.0%-100%) after administration of the quadrivalent vaccine. Oral fluid may have the potential to be used for monitoring of prophylactic HPV vaccines in the future.
Publication types
-
Evaluation Study
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Viral / analysis
-
Antibodies, Viral / immunology*
-
Exudates and Transudates / immunology*
-
Female
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
-
Human papillomavirus 16 / immunology*
-
Humans
-
Immunization, Secondary
-
Immunoglobulin G / analysis
-
Immunoglobulin G / immunology*
-
Mouth Mucosa / immunology
-
Papillomavirus Vaccines / immunology*
-
ROC Curve
-
Randomized Controlled Trials as Topic
Substances
-
Antibodies, Viral
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
-
Immunoglobulin G
-
Papillomavirus Vaccines